CIRM Funded Clinical Trials
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Ranging Study of GNSC-001 Evaluating Safety, Pharmacodynamics, and Biomarkers in Knee OA
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Ranging Study of GNSC-001 Evaluating Safety, Pharmacodynamics, and Biomarkers in Knee OA
Disease Area:
Investigator:
Institution:
CIRM Grant:
Award Value:
$11,637,194
Trial Sponsor:
Genascence Corporation
Trial Stage:
Phase 1
Trial Status:
Launching
Targeted Enrollment:
N/A
